OPT Opthea
WatchlistOpthea News
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Express News | Opthea Limited Appoints Frederic Guerard As Chief Executive Officer Effective Immediately; Guerard To Replace Megan Baldwin Who Will Transition To Founder And Chief Innovation Officer Post; Company Also Appoints Peter Lang As Chief Financial Officer
Opthea Limited's Strong Financial Standing and Promising Drug Candidate Secure a Buy Rating: An Analysis by Chris Cooper
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Opthea Completes Retail Entitlement Offer; Shares Fall 3%
Opthea (ASX:OPT) completed the retail component of its 1-for-3.07 nonrenounceable entitlement offer. The retail entitlement offer raised AU$16.3 million, with eligible shareholders taking up about 8.1
Opthea's Options Suspended From Quotation on ASX; Shares Rise 3%
The options of Opthea (ASX:OPT), trading under the ticker OPTOA on the Australian Securities Exchange, will be suspended immediately from quotation on the index, the biopharmaceutical company said Fri
JonesTrading Sticks to Its Buy Rating for Opthea Limited Sponsored ADR (OPT)
Oppenheimer Cuts Opthea Price Target to $16 From $31, Maintains Outperform Rating
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: Price: 2.33, Change: +0.06,
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Mirati Therapeutics (MRTX) and Opthea Limited Sponsored ADR (OPT)
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 225 companies set new 52-week lows. Significant Points From Today's 52-Week Lows: Norfolk Southern (NYSE:NSC) was the largest, in terms of market cap, to set a new 52-week low.G
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Opthea Opens AU$16 Million Retail Entitlement Offer
Biopharmaceutical company Opthea (ASX:OPT) on Thursday opened a retail entitlement offer to raise AU$16.3 million. Shares under the retail entitlement offer come with 1-for-2 options exercisable at AU
Top Midday Decliners
NovoCure (NVCR) said Monday its phase 3 trial evaluating tumor treating fields with paclitaxel in patients with platinum-resistant ovarian cancer failed to meet its primary endpoint of overall surviva
12 Health Care Stocks Moving In Monday's Intraday Session
GainersBionomics (NASDAQ:BNOX) stock moved upwards by 32.7% to $2.03 during Monday's regular session. Trading volume for Bionomics's stock is 3.0 million as of 13:30 EST. This is 4392.4% of its averag
Opthea Raises Additional Capital, up to $57.6M
H.C. Wainwright Remains a Buy on Opthea Limited Sponsored ADR (OPT)
HC Wainwright & Co. Reiterates Buy on Opthea, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Opthea (NASDAQ:OPT) with a Buy and maintains $14 price target.
Opthea Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 08/01/2023 346.57% HC Wainwright & Co. → $14 Reiterates Buy → Buy 05/16/2023 633.65% EF Hutton → $23 Reite
Analysts Offer Insights on Healthcare Companies: Opthea Limited (OtherCKDXF) and Glaukos (GKOS)